Skip to content
Download PDF

The Bradyarrhythmias: Disorders of the Sinoatrial Node

Chapter 251 | Part 6: Disorders of the Cardiovascular System · Part 6 – Cardiovascular Disorders · Chapter 251

Key Clinical Points

  1. The sinoatrial (SA) node serves as the natural pacemaker with variable rates in response to parasympathetic and sympathetic stimulation.
  2. Intrinsic heart rate is approximately 100 beats/min in denervated hearts, reflecting uninhibited sinus node automaticity.
  3. Intrinsic heart rate declines 5–6 beats/min for each decade of age due to loss of pacemaker cells and fibrosis.
  4. Symptomatic sinus node dysfunction (SND) requires permanent pacemaker implantation; asymptomatic bradycardia does not.
  5. Reversible causes of SND include hypothyroidism, sleep apnea, hypoxia, hypothermia, and medications (beta-blockers, calcium channel blockers, digoxin).
  6. Tachy-brady syndrome consists of high heart rates (e.g., atrial fibrillation) alternating with symptomatic bradycardia or offset pauses.
  7. Permanent pacing is indicated for symptomatic sinus bradycardia, tachy-brady syndrome, and symptomatic chronotropic incompetence.
  8. Leadless pacemakers are available to reduce risks associated with transvenous lead systems (infection, lead fracture).
  9. Carotid sinus hypersensitivity with a cardioinhibitory variant responds to pacemaker implantation.
  10. Sinus node ischemia can lead to slowing of phase 4 depolarization; revascularization may alleviate bradycardia.

DEFINITION & OVERVIEW

• Sinoatrial (SA) Node: The natural pacemaker of the heart with variable rates in response to parasympathetic and sympathetic stimulation. • SND Definition:

Definition (Harrison's 22e): Sinus node dysfunction (SND) or sick sinus syndrome refers to a group of related conditions comprising problems of both impulse formation and impulse conduction. • Consequences of Dysfunction: If the sinus node is dysfunctional or suppressed, a subsidiary pacemaker in the atrioventricular (AV) node or specialized conduction system will take over, leading to a junctional or ventricular rhythm. • Clinical Presentation: Symptoms typically include fatigue, exercise intolerance, or dyspnea.

Structure and Physiology of the SA Node

• Anatomy: Complex structure; clusters of myocytes with pacemaker activity are surrounded by fibroblasts, endothelial cells, and transitional cells. • Location: Sulcus terminalis on the epicardial surface at the right atrial–superior vena cava junction. • Vascularity: SA nodal artery arises from the right coronary artery in 55–60% of persons and the left circumflex artery in 40–45% of persons. • Cellular Characteristics: Prototypic cells have fewer distinct myofibrils, no intercalated disks, poorly developed sarcoplasmic reticulum, and no T tubules. • Electrical Isolation: Protected by a connective tissue matrix to insulate the SA node from the hyperpolarizing influence of the larger atrium; allows for nearly unidirectional electrical propagation.

Action Potential and Automaticity

• Mechanism: Pacemaker cells spontaneously depolarize in a continuous manner. • Baseline Rate: 60–100 beats/min (influenced by parasympathetic predominance). • Intrinsic Heart Rate: Approximately 100 beats/min in denervated hearts (reflects uninhibited sinus node automaticity). • Phase 4 Depolarization: Slow diastolic depolarization; the primary driver of automaticity. • Ion Currents: - I_f (funny current), I_{Ca-T} (T-type calcium), and I_{Ca-L} (L-type calcium) drive phase 4. - Phase 0: Slow upstroke mediated by calcium rather than sodium (sodium channels are absent in SA node cells). - Phase 3: Repolarization via potassium currents (I_K). • Age Impact: Intrinsic heart rate declines 5–6 beats/min for each decade of age due to loss of pacemaker cells and fibrosis.

EPIDEMIOLOGY

• Prevalence: Clinical SND is most common in older adults. • Pathophysiology of Aging: - Age-associated increase in fibrotic tissue in the SA node. - Loss of pacemaker cells in the sinus node. - Transition to predominant sympathetic tone by the ninth decade.

ETIOLOGY & PATHOPHYSIOLOGY

• Sinus Node Dysfunction (SND): Also known as sick sinus syndrome; manifests as fatigue, exercise intolerance, or syncope resulting from either reduced heart rate or pauses. • Ischemia: - Reduced blood flow to the SA node (often via right coronary artery) can slow phase 4 depolarization. - Result: Bradycardia or pauses. - Revascularization may alleviate bradycardia in cases of ischemia. • Iatrogenic Injury: Potential for injury to the SA nodal artery during atrial fibrillation catheter ablation.

Reversible Causes

• Clinical Rule: In patients <85 years of age, heart rate is strongly influenced by parasympathetic tone. • Table 251-1: Reversible Causes of Sinus Node Dysfunction - Medical Conditions: Hypothyroidism, Sleep apnea, Hypoxia, Hypothermia, Increased intracranial pressure, Lyme disease, Myocarditis, COVID-19, Vagal reflex (cough, pain, etc.). - Medications: - Antihypertensives: Beta-blocker, Clonidine, Methyldopa, Nondihydropyridine calcium channel blockers. - Antiarrhythmics: Amiodarone, Dronedarone, Flecainide, Procainamide, Propafenone, Quinidine, Sotalol, Ivabradine. - Psychiatric: Donepezil, Lithium, Opioid analgesics, Phenothiazine antiemetics and antipsychotics, Phenytoin, SSRIs, TCAs. - Other: Anesthetic drugs (propofol), Cannabis, Digoxin, Muscle relaxants.

Pathologic Subtypes

• Impulse Formation vs. Conduction: - Sinoatrial exit block: Failure of sinus node activity to propagate to the atrium. - Type I SA block: Fixed delay out of the sinus node. - Type II SA block: - Mobitz I type: Progressive delay and then intermittent failure to propagate to the atrium. - Mobitz II type: Fixed delay with intermittent failure to conduct. - Sinoatrial Wenckebach: Progressively shortening of the P-P interval leading up to a sinus pause (due to progressive prolongation of SA conduction, but to a lesser extent with each successive prolongation).

CLINICAL FEATURES

• General Symptoms: Fatigue, exercise intolerance, dyspnea, syncope. • Chronotropic Incompetence (CI): - Definition: Inability of the heart to increase its rate to meet activity/demand. - Impact: Primary cause of severe exercise intolerance and increased mortality. - Assessment Criteria: - Failure to achieve ≥ 85% of age-predicted max heart rate $[(220 - ext{age}) imes 0.85]$. - Maximum heart rate $[208 - (0.7 imes ext{age})]$. - Heart rate instability with exercise or failure to achieve submaximal heart rate. • Tachy-brady Syndrome: - Definition: High heart rates (most commonly atrial fibrillation) with alternating symptomatic bradycardia or offset pauses. - Management Note: Rate control medications for tachycardia often exacerbate bradycardia episodes. • Carotid Sinus Hypersensitivity: - Cardioinhibitory variant associated with vasovagal syncope responds to pacemaker implantation.

• Mechanism: High vagal tone during sleep, especially during apneic events. • Clinical Note: Asymptomatic bradycardia/pauses during sleep are typically not an indication for pacing.

Post-Transplant Bradycardia

• Context: Expected heart rate in transplant recipients is 90–110 beats/min due to denervation. - Diagnosis: A rate that is normal in a non-transplant patient may represent CI in a transplanted patient. - Causes: Drug accumulation (amiodarone) or ischemic injury during surgery.

DIFFERENTIAL DIAGNOSIS

• Age Factor: In patients <85 years, heart rate is heavily influenced by parasympathetic tone. • Rule of Exclusion: Identify and eliminate reversible causes (Hypothyroidism, Sleep Apnea, Medications) before considering permanent pacing.

Reversible vs. Irreversible Causes

• Asymptomatic Bradycardia: Not associated with adverse outcomes; does not warrant pacing. - Exceptions: Symptomatic bradycardia, tachy-brady syndrome, or symptomatic CI.

DIAGNOSTIC APPROACH

  1. Initial Evaluation:
  2. Perform ECG to detect baseline sinus bradycardia.
  3. Identify and eliminate reversible causes (Table 251-1).
  4. Symptom Correlation:
  5. Use ambulatory monitoring (Holter, mobile cardiac telemetry) or wearable devices to correlate symptoms with heart rate/pauses.
  6. Exercise testing: Assess for maximum heart rate and chronotropic incompetence.
  7. Structural Assessment:
  8. Transthoracic echocardiography if structural disease is suspected.
  9. Advanced imaging (Class IIa) if infiltrative cardiomyopathy, endocarditis, or ACHD is suspected.
  10. Invasive Electrophysiology Study (EPS):
  11. Indicated only if diagnosis remains uncertain after noninvasive evaluation.
  12. Parameters: SNRT, SACT, and intrinsic heart rate calculation $[118.1 - (0.57 imes ext{age})]$.
  13. Decision Logic for Pacing:
  14. Symptom correlation → Yes → Proceed to pacing evaluation.
  15. Symptom correlation → No → Observation is appropriate.

Evaluation of Bradycardia and Conduction Disease (Flowchart 1)

  1. Treatment Evaluation:
  2. Is treatment effective or unnecessary?
  3. Yes → Observe.
  4. No → Proceed to Structural Heart Disease assessment.
  5. Structural Heart Disease Assessment:
  6. Suspicion for structural heart disease?
  7. Yes → Transesophageal echocardiography (Class IIa) → Suspicion for infiltrative CM, endocarditis, ACHD?
  8. Yes → Advanced imaging (Class IIa) → Treat identified abnormalities.
  9. No → Treat identified abnormalities.
  10. No → Proceed to Symptom Assessment.
  11. Symptom Assessment:
  12. Symptoms present?
  13. No → Observe.
  14. Yes → Exercise related?
  15. Yes → Exercise ECG testing (Class IIa).
  16. No → Ambulatory ECG monitoring (Class I).
  17. Diagnostic Determination:
  18. Is a definitive diagnosis required?
  19. Yes → Electrophysiology study (if performed for other reasons) (Class IIb).
  20. No → Ambulatory ECG monitoring (Class I).

MANAGEMENT & TREATMENT

  1. Initial Management:
  2. Identify and eliminate reversible causes (e.g., adjust dosage of beta-blockers, CCBs, or digoxin; treat hypothyroidism/sleep apnea).
  3. Tachy-brady Syndrome Treatment:
  4. Address underlying tachycardia (atrial fibrillation) to prevent bradycardia events.
  5. Permanent Pacemaker (PPM) Indications:
  6. Symptomatic sinus bradycardia due to essential medication therapy with no alternative.
  7. Tachy-brady syndrome with symptoms attributable to bradycardia.
  8. Symptomatic chronotropic incompetence.
  9. Trial of oral theophylline may be used to determine if pacing is beneficial (Table 251-2).
  10. Pacing Selection Strategy:
  11. High Risk/Comorbidity: If patient has significant comorbidities or requires infrequent pacing → Single chamber, ventricular pacing (Class IIa).
  12. No RV Lead Requirement: If no reason to avoid an RV lead and normal AV conduction is present → Single chamber, atrial pacing (Class I).
  13. Standard Case: If no specific contraindications exist → Dual chamber pacing (Class I).
  14. Pharmacological Trial:
  15. If response suggests symptomatic SND but patient is unwilling to have a PPM or if correlation is unclear → Oral theophylline (Class IIb).

Management of Sinus Node Dysfunction (Flowchart 2)

  1. High Risk/Comorbidity Pathway:
  2. Infrequent pacing? Significant comorbidities? → Yes → Single chamber, ventricular pacing (Class IIa).
  3. Specific Anatomical Constraints Pathway:
  4. Infrequent pacing? Significant comorbidities? → No → Normal AV conduction and reason to avoid an RV lead? → Yes → Single chamber, atrial pacing (Class I).
  5. Standard Management Pathway:
  6. Infrequent pacing? Significant comorbidities? → No → Normal AV conduction and reason to avoid an RV lead? → No → Dual chamber pacing (Class I).
  7. Uncertain Symptom Correlation Pathway:
  8. Response suggests symptomatic sinus node dysfunction? → No → Oral theophylline (Class IIb).
  9. Confirmed Symptomatic SND Pathway:
  10. Response suggests symptomatic sinus node dysfunction? → Yes → Willing to have a PPM?
  11. Yes → Program to minimize ventricular pacing (Class IIa).
  12. No → Oral theophylline (Class IIb).

PROGNOSIS & COMPLICATIONS

• Symptom Correlation: The stronger the correlation between symptoms and bradycardia, the greater the likelihood of improvement with pacing. • Tachy-brady Syndrome: Often requires management of both tachycardia (to eliminate bradycardia) and potential pacemaker placement.

SPECIAL POPULATIONS

• Sleep Apnea Patients: High vagal tone during apnea leads to sinus bradycardia/pauses; these are typically not indications for pacing. • Heart Transplant Recipients: Normal heart rate is 90–110 bpm due to denervation; lower rates may indicate chronotropic incompetence.

KEY PEARLS & HIGH-YIELD POINTS

• Symptom Correlation is Key: Only symptomatic bradycardia or tachycardia-bradycardia syndrome warrants a pacemaker. • Rule out Reversibles First: Always check for hypothyroidism, sleep apnea, and medication effects (Beta-blockers, CCBs, Digoxin) before permanent pacing. • SA Block Differentiation: - Type I: Fixed delay (Sinoatrial exit block). - Type II: Progressive or fixed intermittent failure (Mobitz-like patterns). • Chronotropic Incompetence: A critical but often overlooked cause of exercise intolerance; requires specific assessment via exercise testing. • Leadless Pacemakers: Available to reduce risks associated with transvenous lead systems (infection, lead fracture).

Reference Tables

TABLE 251-1 Reversible Causes of Sinus Node Dysfunction Medical Conditions Associated with Sinus Bradycardia •…

Harrison's 22e, p.1920

  • Medical Conditions Associated with Sinus Bradycardia
  • • Hypothyroidism
    • Sleep apnea
    • Hypoxia
    • Hypothermia
    • Increased intracranial pressure
    • Lyme disease
    • Myocarditis
    • COVID-19
    • Vagal reflex (cough, pain, etc.)
  • Medications Associated with Sinus Node Dysfunction
  • Antihypertensive Medications
    • Beta-adrenergic receptor blockers
    • Clonidine
    • Methyldopa
    • Nondihydropyridine calcium channel blockers
    Antiarrhythmic Medications
    • Amiodarone
    • Dronedarone
    • Flecainide
    • Procainamide
    • Propafenone
    • Quinidine
    • Sotalol
    • Ivabradine
    Psychiatric Medications
    • Donepezil
    • Lithium
    • Opioid analgesics
    • Phenothiazine antiemetics and antipsychotics
    • Phenytoin
    • Selective serotonin reuptake inhibitors
    • Tricyclic antidepressants
    Other
    • Anesthetic drugs (propofol)
    • Cannabis
    • Digoxin
    • Muscle relaxants

TABLE 251-2 Indications for Permanent Pacing in Sinus Node Dysfunction (SND) • Symptoms that are directly attributable…

Harrison's 22e, p.1923

  • • Symptoms that are directly attributable to SND
    • Symptomatic sinus bradycardia because of essential medication therapy for
    which there is no alternative treatment
    • Tachy-brady syndrome and symptoms attributable to bradycardia
    • Symptomatic chronotropic incompetence
    • In patients with symptoms that are possibly attributable to SND, a trial of
    oral theophylline may be considered to increase heart rate and determine if
    permanent pacing may be beneficial